Intranigral iron infusion in the rat: Acute elevations in nigral lipid peroxidation and striatal dopaminergic markers with ensuing nigral degeneration

Biological Trace Element Research

Volumn 58, Issue 3, 1997, Pages 177-195

  Sengstock, Gregory J ^a   Zawia, Nasser H ^b   Olanow, Charles W ^c   Dunn, Adrian J ^d   Arendash, Gary W ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b MEHARRY MEDICAL COLLEGE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

Dopamine; Iron infusion; Lipid peroxidation; Parkinson's disease; Rat; Substantia nigra; Thiobarbituric acid reactive products

Indexed keywords

IRON; THIOBARBITURIC ACID;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; DOPAMINE BRAIN LEVEL; DOPAMINERGIC TRANSMISSION; INFUSION; IRON METABOLISM; LIPID PEROXIDATION; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; RAT; SUBSTANTIA NIGRA;

ANIMALIA;

EID: 0030727141     PISSN: 01634984     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02917470     Document Type: Article

References (68)

1. L. Forno, Pathology of Parkinson's disease, in Movement Disorders, C. Marsden and S. Fhan, eds., Butterworths, London, pp. 25-40 (1982).
2. K. Earle, Studies in Parkinson's disease including x-ray fluorescent spectroscopy of formalin fixed brain tissue, J. Neuropathol. Exp. Neurol. 27, 1-14 (1968).
3. E. Sofic, P. Riederer, H. Heinsen, H. Beckmann, G. Reynolds, G. Hebenstreit, and M. Youdim, Increased iron (III) and total iron content in post mortem substantia nigra of Parkinsonian brain, J. Neural Transm. 74, 199-205 (1988).
4. D. Dexter, F. Wells, A. Lees, F. Agid, Y. Agid, P. Jenner, and C. Marsden, Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease, J. Neurochem. 52, 1983-1836 (1989).
5. P. Riederer, E. Sofic, W. Rausch, B. Schmidt, G. Reynolds, K. Jellinger, and M. Youdim, Transition metals, ferritin, glutathione, and ascorbic acid in Parkinsonian brains, J. Neurochem. 52, 515-520 (1989).
6. E. Hirsch, J.-P. Brandel, P. Galle, F. Javoy-Agid, and Y. Agid, Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an x-ray microanalysis, J. Neurochem. 56, 446-451 (1991).
7. K. Jellinger, W. Paulus, I. Grundke-Iqbal, P. Riederer, and M. Youdim, Brain iron and ferritin in Parkinson's and Alzheimer's diseases, J. Neural Transm. 2, 327-340 (1990).
8. E. Sofic, W. Paulus, K. Jelling, P. Riederer, and M. Youdim, Selective increase of iron in substantia nigra zona compacta of parkinsonian brains, J. Neurochem. 56, 978-982 (1991).
9. S. Fahn, The endogenous toxin hypothesis of the etiology of Parkinson's disease and a pilot trial of high-dosage antioxidants in an attempt to slow the progression of the illness, Ann. NY Acid. Sci 570, 186-196 (1989).
10. P. Jenner, Oxidative stress as a cause of Parkinson's disease, Acta Neurol. Scand. 84, 6-15 (1991).
11. S. Fahn and G. Cohen, The oxidant stress hypothesis in Parkinson's disease: evidence supporting it, Ann. Neurol 32, 804-812 (1992).
12. C. Olanow and G. Cohen, The pathogenesis of Parkinson's disease, in The Scientific Basis for the Treatment of Parkinson's Disease, C. Olanow and A. Liedermann, eds., Parthenon Publishing, New Jersey, pp. 59-76 (1992).
13. C. Olanow and G. Arendash, Metals and free radicals in neurodegeneration, Curr. Opin. Neurol. 7, 548-558 (1994).
14. B. Halliwell, Oxygen radicals as key mediators in neurological disease: fact or fiction? Ann. Neurol. 32, S10-S15 (1992).
15. B. Halliwell, Reactive oxygen species and the central nervous system, J. Neurochem. 59, 1609-1623 (1992).
16. M. Zaleska and R. Floyd, Regional lipid peroxidation in rat brain in vivo: possible role of endogenous iron, Neurochem. Res. 10, 397-410 (1985).
17. M. Braughler, L. Duncan, and R. Chase, The involvement of iron in lipid peroxidation, J. Biol. Chem. 261, 10282-10289 (1986).
18. M. Zaleska, K. Nagy, and R. Floyd, Iron-induced lipid peroxidation and inhibition of dopamine synthesis in striatum synaptosomes, Neurochem. Res. 14, 597-606 (1989).
19. K. Subbarao and J. Richardson, Iron-dependent peroxidation of the rat brain: a regional study, J. Neurosci. Res. 26, 224-232 (1990).
20. B. Halliwell and J. Gutteridge, Oxygen radicals and the nervous system, TINS 8, 22-26 (1985).
21. J. Gutteridge, The role of superoxide and hydroxyl radicals in phospholipid peroxidation catalysed by iron salts, Febs. Lett. 150, 454-458 (1982).
22. J. Gutteridge and B. Halliwell, The measurement and mechanism of lipid peroxidation in biological systems, TIBS 15, 129-135 (1990).
23. 2 into rat isocortex, Brain Res. 246, 113-119 (1982).
24. 2+ injection, J. Neurochem. 42, 976-980 (1984).
25. J. Braughler, R. Chase and J. Pregenzer, Stimulation and inhibition of iron-dependent lipid peroxidation by desferrioxamine, Biochem. Biophys. Res. Commun, 153, 933-938 (1988).
26. M. Ciuffi, G. Gentilini, S. Franchi-Micheli, and L. Zilletti, Lipid peroxidation induced "in vivo" by iron-carbohydrate complex in rat brain cortex, Neurochem. Res. 16, 43-49 (1991).
27. M. Gotz, A. Dirr, W. Gsell, R. Burger, A. Freyburger, and P. Riederer. Some reflections on iron dependent free radical damage in the central nervous system, in Key Topics in Brain Research: Iron in Central Nervous System Disorders, P. Riederer and M. Youdim, eds., Springer-Verlag, Wien/New York, pp. 45-54 (1993).
28. B. Halliwell, Oxidants and the central nervous system: some fundamental questions, Acta Neurol. Scand. 126, 23-33 (1989).
29. R. Floyd and J. Carney, Free radical damage to protein and DNA: mechanisms involved and relevant observations on brain undergoing oxidative stress, Ann. Neurol. 32, S22-S27 (1992).
30. E. Hirsch, A. Graybiel, and Y. Agid, Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease, Nature 334, 345-348 (1988).
31. H. Swartz, T. Sarna, and L. Zecca. Modulation by neuromelanin of the availability and reactivity of metal ions, Ann. Neurol. 32, S69-S75 (1992).
32. S. Aime, M. Fasano, B. Bergamasco, L. Lopiano, and G. Valente. Evidence for a glycidic-lipidic matrix in human neuromelanin, potentially responsible for the enhanced iron sequestering ability of substantia nigra, J. Neurochem. 62, 369-371 (1994).
33. D. Ben-Shachar, P. Riederer, and M. Youdim. Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease, J. Neurochem. 57, 1609-1614 (1991).
34. M. Youdim, D. Ben-Shachar, and P. Riederer, Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol. Scand. 126, 47-54 (1989).
35. G. Minotti and S. Aust, The requirement for iron (III) in the initiation of lipid peroxidation by iron (II) and hydrogen peroxide, J. Biol. Chem. 262, 1098-1104 (1987).
36. M. Tanaka, A. Sotomatsu, H. Kanal, and S. Hirai, Dopa and dopamine cause cultured neuronal death in the presence of iron, J. Neurol. Sci. 101, 198-203 (1991).
37. P. Michel, S. Vyas, and Y. Agid, Toxic effects of iron for cultured mesencephalic dopaminergic neurons derived from rat embyonic brains, J. Neurochem. 59, 118-127.
38. H. Bereimer, W. Birkmayer, O. Hornykiewicz, K. Jellinger, and F. Seitelberger, Brain dopamine and the syndromes of Parkinson and Huntington, J. Neurol. Sci. 20, 415-455 (1973).
39. M. Zigmond, E. Abercrombie, T. Berger, A. Grace, and E. Stricker, Compensations after lesions of central dopaminergic neurons: some clinical and basic implications, TINS 13, 290-296 (1990).
40. T. Perry, D. Godin, and S. Hansen. Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci. Lett. 33, 305-310 (1982).
41. P. Jenner, D. Dexter, J. Sian, A. Schapira, and C. Marsden, Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental lewy body disease, Ann. Neurol. 32, S82-S87 (1992).
42. E. Sofic, K. Lange, K. Jellinger, and P. Riederer, Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease, Neurosci. Lett. 142, 128-130 (1992).
43. H. Saggu, J. Cooksey, D. Dexter, F. Wells, A. Lees, P. Jenner, and C. Marsden, A selective increase in particulate superoxide dismutase activity in Parkisonian substantia nigra, J. Neurochem. 53, 692-697 (1989).
44. P. Good, C. Olanow, and D. Perl, Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study, Brain Res. 593, 343-346 (1992).
45. K. Jellinger, E. Kienzl, G. Rumpelmair, P. Riederer, H. Stachelberger, D. Ben-Shachar, and M. Youdim, Iron-melanin complex in substantia nigra of Parkinsonian brains: an x-ray microanalysis, J. Neurochem. 59, 1168-1171 (1992).
46. D. Dexter C. Carter, A. Wells, F. Javoy-Agid, Y. Agid, A. Lees, P. Jenner, and C. Marsden, Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease, J. Neurochem. 52, 381-389 (1989).
47. G. Sengstock C. Olanow, A. Dunn, and G. Arendash, Iron induces degeneration of nigrostriatal neurons, Brain Res. Bull. 28, 645-649 (1992).
48. G. Sengstock, C. Olanow, R. Menzies, A. Dunn, and G. Arendash, Infusion of iron into the rat substantia nigra: nigral pathology and dose-dependent loss of striatal dopaminergic markers, J. Neurosci. Res. 35, 67-82 (1993).
49. G. Sengstock, C. Olanow, A. Dunn, S. Barone, and G. Arendash, Progressive changes in striatal dopaminergic markers, nigral volume, and rotational behavior following iron infusion into the rat substantia nigra, Exp. Neurol. 130, 82-94 (1994).
50. J. Buege and S. Aust, Microsomal lipid peroxidation, Methods Enzymol. 52, 302-310 (1978).
51. A. Dunn, Stress-related changes in cerebral catecholamine and indoleamine metabolism: lack of effect of adrenalectomy and corticosterone, J. Neurochem. 51, 406-412 (1988).
52. J. Hill and R. Switzer III, The regional distribution and cellular localization of iron in the rat brain, Neurosci. 11, 595-603 (1984).
53. E. Wills, The effect of inorganic iron on the thiobarbituric acid method for the determination of lipid peroxides, Biochim. Biophys. Acta 84, 475-477 (1964).
54. H. Draper and M. Hadley, Malondialdehyde determination as index of lipid peroxidation, Methods Enzymol. 186, 421-431 (1989).
55. D. Janero and B. Burghardt, Thiobarbitunic acid-reactive malondialdehyde formation during superoxide-dependent, iron-catalyzed lipid peroxidation: influence of peroxidation conditions, Lipids 24, 125-131 (1989)
56. B. Halliwell and J. Gutteridge, Free Radicals in Biology and Medicine, Oxford University Press, New York, pp. 228-233 (1989).
57. H. Esterbauer and K. Cheeseman, Determination of aldehydic lipid peroxidation products: malondialdehyde and 4-hydroxynonenal, Methods Enzymol. 186, 407-421 (1990).
58. E. Westerberg, B. Akesson, S. Rehncrona, D. Smith, and B. Siesjo, Lipid peroxidation in brain tissue in vitro: effects on phospholipid and fatty acids, Acta Physiol. Scand. 105, 524-526 (1979).
59. 2+ - and ascorbic acid-stimulated lipid peroxidation in vitro, J. Neurochem. 34, 1630-1638 (1980).
60. J. Connor, S. Menzies, S. St. Martin, and E. Mufson, Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains, J. Neurosci. Res. 27, 595-611 (1990).
61. P. Damier, E. Hirsch, P. Zhang, Y. Agid, and F. Javoy-Agid, Glutathione peroxidase, glial cells and Parkinson's disease, Neurosci. 52, 1-6 (1993).
62. M. Gerber and J. Connor, Do oligodendrocytes mediate iron regulation in the human brain? Ann. Neurol. 26, 95-98 (1989).
63. J. Connor, Cellular and regional maintenance of iron homeostasis in the brain: normal and diseased states, in Key Topics in Brain Research: Iron in Central Nervous System Disorders, P. Riederer and M. Youdim, eds., Springer-Verlag, Wien/New York, pp. 1-18 (1993).
64. D. Ben-Shachar and M. Youdim, Intranigral iron injection induces behavioral and biochemical "parkinsonism" in rats, J. Neurochem. 57, 2133-2135 (1991).
65. W. Wesemann, S. Blaschke, H.-W. Clement, C. Grote, N. Weiner, W. Kolasiewicz, and K.-H. Sontag, Iron and neurotoxin intoxication: comparative in vitro and in vivo studies, in Key Topics in Brain Research: Iron in Central Nervous System Disorders, P. Riederer and M. Youdim, eds., Springer-Verlag, Wein/New York, pp. 79-86 (1993).
66. 3 and 6-OHDA without and after transient cerebral oligemia on behavior and navigation, in Key Topics in Brain Research: Iron in Central Nervous System Disorders, P. Riederer and M. Youdim, eds., Springer-Verlag, Wien/New York, pp. 138-153 (1993).
67. W. Sloot, A. vander Sluijs-Gelling, and J. Gramsbergen, Selective lesions by manganese and extensive damage by iron after injection into rat striatum or hippocampus, J. Neurochem. 62, 205-216 (1994).
68. Y. Mizuno H. Mochizuki, K. Nishi, S.-I. Ikebe, N. Hattori, and Y. Hattori-Nakagawa, Pathogenesis of Parkinson's disease; iron and mitochondrial DNA deletion, in Key Topics in Brain Research: Iron in Central Nervous System Disorders, P. Riederer and M. Youdim, eds., Springer-Verlag, Wien/New York, pp. 117-135 (1993).